Caricamento...
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
BACKGROUND: AMPLIFY assessed the efficacy and safety of aclidinium bromide/formoterol fumarate (AB/FF) vs its monocomponents and tiotropium (TIO) in patients with moderate-to-very severe symptomatic COPD (NCT02796677). METHODS: In this 24-week, Phase III, double-dummy, active-controlled study, sympt...
Salvato in:
| Pubblicato in: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435124/ https://ncbi.nlm.nih.gov/pubmed/30962681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S189138 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|